Home › NDC Lookup › RxCUI directory › RxCUI 828537

Rizatriptan 10 MG Disintegrating Oral Tablet [Maxalt] — RxCUI 828537

RxNorm drug concept · Semantic branded drug
RxCUI 828537 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI828537
Official nameRizatriptan 10 MG Disintegrating Oral Tablet [Maxalt]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMaxalt 10 MG Disintegrating Oral Tablet; Maxalt-MLT 10 MG Disintegrating Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)51 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rizatriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats a migraine attack once it has started, with or without aura. It works for adults and for children 6 to 17. It does not prevent migraines and is not for cluster headache.
  • Take it by mouth when a migraine begins. Tablets are swallowed, while the dissolving tablets and Rizafilm melt in your mouth. You can take it with or without food. If the headache...
  • The most common are tiredness, sleepiness, dizziness, tingling and pain or pressure sensations. Tightness in the chest, throat or jaw can happen and is usually not heart-related, b...
  • Seek emergency help for chest pain, sudden weakness or trouble speaking, a racing heartbeat, swelling of the face or throat, or severe stomach pain with bloody diarrhea. Also seek...
📖 Read our full Rizatriptan guide →

🕸️ Concept Web — How Rizatriptan 10 MG Disintegrating Oral Tablet [Ma... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Rizatriptan 10 MG Disintegrating Oral Tablet [Maxalt] RxCUI 828537

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Rizatriptan 88014
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Maxalt 218248
  3. Dose forms 12

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Rizatriptan Disintegrating Oral Tablet 374590
    • Rizatriptan Disintegrating Oral Product 1295097
    • Rizatriptan Oral Product 1157975
    • Rizatriptan Pill 1157976
    • Rizatriptan Disintegrating Oral Tablet [Maxalt] 828535
    • Maxalt Disintegrating Oral Product 1295826
    • Maxalt Oral Product 1181574
    • Maxalt Pill 1181575
    • +4 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Rizatriptan 10 MG Disintegrating Oral Tablet SCD · 312837
  • Rizatriptan 10 MG SCDC · 330765
  • Rizatriptan Disintegrating Oral Tablet SCDF · 374590
  • Rizatriptan Disintegrating Oral Product SCDG · 1295097
  • Rizatriptan Oral Product SCDG · 1157975
  • Rizatriptan Pill SCDG · 1157976

Brand-Name Concepts

  • Rizatriptan 10 MG [Maxalt] SBDC · 573223
  • Rizatriptan Disintegrating Oral Tablet [Maxalt] SBDF · 828535
  • Maxalt Disintegrating Oral Product SBDG · 1295826
  • Maxalt Oral Product SBDG · 1181574
  • Maxalt Pill SBDG · 1181575
  • Maxalt BN · 218248

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 828537 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
78206-0142-01 18 POUCH in 1 CARTON (78206-142-01) / 1 TABLET in 1 POUCH (... MAXALT Organon LLC 2021-06-01
78206-0143-01 6 CONTAINER in 1 CARTON (78206-143-01) / 3 POUCH in 1 CONTA... MAXALT-MLT Organon LLC 2021-06-01
Observed labelers: Organon LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.